An Essential Framework to Navigating Technical Challenges in Contemporary OSD Development

Why It Matters

By embedding risk assessment and QbD early, companies can shorten development cycles, lower costs, and improve launch success for high‑risk oral solid products, a critical advantage in a market where demand for complex OSD forms is accelerating.

Key Takeaways

• 70‑90% of new small‑molecule candidates exhibit poor aqueous solubility
• Early physicochemical profiling predicts degradation and guides excipient selection
• QbD tools like FMEA and DoE define critical quality attributes
• Patheon’s CDMO scale‑up capability aligns lab processes with commercial output

Pulse Analysis

The oral solid dosage market is expanding as patients and payers demand convenient, value‑added tablet and capsule formats. Yet the surge in BCS Class II and IV molecules—estimated at up to 90 % of pipelines—creates a solubility bottleneck that can stall projects if not addressed early. Compounded by stability concerns such as amorphous crystallisation and moisture sensitivity, developers must anticipate formulation risks well before clinical phases, or risk expensive late‑stage reformulations.

Thermo Fisher Scientific’s Patheon proposes a three‑step risk‑identification framework that starts with exhaustive physicochemical profiling, including multi‑pH solubility, hygroscopicity, and polymorphism screens. Coupled with accelerated stability studies, this data informs excipient compatibility assessments that leverage quantum‑level interaction modeling, dramatically cutting trial‑and‑error cycles. Integrating Quality by Design principles—defining Quality Target Product Profiles, Critical Quality Attributes, and employing Failure Mode Effects Analysis—creates a design space that guides process parameters such as compression force or super‑disintegrant levels, ensuring consistent product performance across scale‑up.

The strategic value of a seasoned CDMO lies in translating this framework into reliable manufacturing. Patheon’s 40‑year OSD pedigree and global network provide matched development and commercial equipment, enabling seamless scale‑up from kilogram‑level labs to 500‑kg production runs. By applying pattern‑recognition from thousands of prior projects, the CDMO reduces uncertainty, accelerates timelines, and offers regulatory flexibility—key differentiators for biopharma firms navigating an increasingly complex oral solid landscape.